
|Videos|August 7, 2017
Dr. Burtness on Challenges Facing Immunotherapy in Head and Neck
Author(s)Barbara Burtness, MD
Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.
Advertisement
Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses challenges regarding immunotherapy for patients with head and neck cancer.
Although immunotherapy can lead to durable responses, there are still a population of patients who do not see any responses, explains Burtness.
According to Burtness, more research needs to be conducted in an attempt to make all patients respond to immunotherapy or to determine a targeted therapy to better support the immune system.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































